Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss PartyThe Motley Fool • 05/19/26
Can Novo Nordisk Sustain Its GLP-1 Edge Amid Lilly's Growing Pressure?Zacks Investment Research • 05/14/26
Viking Therapeutics Presents Data from its 13-Week Phase 2 VENTURE-Oral Dosing Trial of VK2735 at European Congress on Obesity (ECO) 2026PRNewsWire • 05/12/26
Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (ECO) 2026PRNewsWire • 05/05/26
Viking Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate UpdatePRNewsWire • 04/29/26
This Obesity Stock Could More Than Double Over the Next 12 Months, According to Wall StreetThe Motley Fool • 04/26/26
Viking Therapeutics, Inc. (VKTX) Suffers a Larger Drop Than the General Market: Key InsightsZacks Investment Research • 04/23/26
Viking Therapeutics to Report Financial Results for First Quarter 2026 on April 29, 2026PRNewsWire • 04/22/26
Viking Therapeutics Gears Up for Q1 Earnings: Here's What to ExpectZacks Investment Research • 04/21/26
Is Viking Therapeutics the Ultimate Millionaire-Maker Obesity Stock for 2026?The Motley Fool • 04/17/26
Viking Therapeutics, Inc. (VKTX) Surpasses Market Returns: Some Facts Worth KnowingZacks Investment Research • 04/13/26
Viking Therapeutics, Inc. (VKTX) Stock Dips While Market Gains: Key FactsZacks Investment Research • 04/06/26